Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00074529 | Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED) | PHASE2 | COMPLETED | 512 | — | — | Oct 1, 2003 | Jan 1, 2006 | Jul 24, 2015 | - | — |
| Name | Type | Description |
|---|---|---|
| MK0677 | DRUG | - |
* Patients must have probable Alzheimer's disease of mild or moderate severity. * A brain scan and laboratory results must be consistent with Alzheimer's disease. * The patient must be otherwise medically healthy.